본문 바로가기
bar_progress

Text Size

Close

Daejeon City, 35% COVID-19 Vaccination Rate Among High-Risk Groups... "Vaccination Recommended for Elderly and Others"

The COVID-19 vaccination rate for high-risk individuals aged 65 and over residing in Daejeon reached 35% as of the 15th of this month. This is the second highest vaccination rate among metropolitan cities.


On the 16th, the Daejeon city government announced that it will operate an intensive COVID-19 vaccination period until the end of next month. The target vaccination rate during this period is 50%, and so far, vaccinations are progressing smoothly according to Daejeon's assessment.


In particular, the vaccines currently used for vaccination have been found to be highly effective against the COVID-19 variant viruses mainly detected in the region, providing a basis for recommending vaccination to high-risk groups.


According to the analysis by the Chungcheong Disease Response Center, among COVID-19 variant virus infections that occurred in Daejeon last month, the EG.5 (including HK.3) type accounted for 91.0%. The monovalent XBB.1.5 vaccines (Pfizer, Moderna) currently used for vaccination show high neutralizing antibody production against the EG.5 variant virus, and Daejeon city believes that the vaccine effect is sufficiently manifested.


Vaccination recipients can receive their shots at nearby clinics or hospitals regardless of their registered residence, and designated COVID-19 vaccination medical institutions can be confirmed through the COVID-19 vaccination website or by phone.


Nam Si-deok, Director of the Citizen Sports and Health Bureau of Daejeon City, said, “Thanks to the active cooperation of citizens, COVID-19 vaccinations are progressing smoothly as originally planned,” and added, “We urge seniors aged 65 and over who have not yet been vaccinated, immunocompromised individuals, and staff of infection-vulnerable facilities to participate in COVID-19 vaccination before the end of the year.”


© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

Special Coverage


Join us on social!

Top